Kernicterus Treatment Global Market Report 2024

The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.88 billion in 2023 to $2.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. The expansion observed in the historical period can be credited to advancements in neonatal care practices, heightened awareness among healthcare professionals, government initiatives focusing on maternal and child health, increased research funding and participation in clinical trials, as well as collaborative efforts in the field of medical research.

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The anticipated growth in the forecast period can be ascribed to ongoing medical education programs, the influence of global health policies and initiatives, the presence of patient advocacy and support groups, international collaboration in pediatric research, and government funding directed towards neonatal health. Prominent trends expected in the forecast period encompass advancements in neonatal jaundice monitoring technologies, the introduction of phototherapy devices with enhanced features, the development of medications to reduce bilirubin levels, a focus on home-based phototherapy solutions, the implementation of bilirubin nomograms and guidelines, and the integration of telehealth for remote monitoring.

The expansion of the kernicterus treatment market is being fueled by the widespread occurrence of neonatal jaundice. Neonatal jaundice, or jaundice in newborns, is a common and generally benign condition characterized by the yellowing of a baby's skin and the whites of their eyes. Kernicterus treatment is a frequently employed approach for neonatal jaundice, aimed at symptom management and providing supportive care. This method involves extracting blood from the infant and replacing it with blood containing a lower bilirubin level, enhancing the affected child's quality of life. For example, in August 2023, as reported by the National Library of Medicine, a US-based biomedical library, approximately 1.1 million infants develop severe neonatal hyperbilirubinemia (neonatal jaundice) globally each year. Additionally, in February 2021, as estimated by ClinMed International Library, a US-based publishing company, at least 114,000 infants succumb annually to neonatal hyperbilirubinemia (neonatal jaundice). Consequently, the prevalence of neonatal jaundice is anticipated to drive the expansion of the kernicterus treatment market.

The expansion of the kernicterus treatment market is being fueled by incremental healthcare spending. Incremental healthcare spending denotes the funds allocated in the healthcare sector to address the rising costs associated with the expansion or enhancement of healthcare services, programs, or infrastructure. In the context of keratosis treatment, incremental healthcare spending is a crucial determinant. It contributes to the improvement of quality and accessibility of care for infants and children affected by kernicterus, playing a vital role in optimizing treatment outcomes and enhancing the quality of life for affected individuals. As an example, a report released by the Office for National Statistics, a UK government department, in May 2023 highlighted that healthcare spending in the UK witnessed a nominal increase of 9.4% and a real increase of 9.7% between 2020 and 2021. In 2021, the total healthcare expenditure in the UK reached $367.25 billion (£280.7 billion), with pharmaceutical expenditure standing at $51.84 billion (£3.96 billion). Notably, spending on preventive care experienced substantial growth, reaching $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Consequently, the growth of the kernicterus treatment market is propelled by incremental healthcare spending.

The growth of the kernicterus treatment market faces limitations due to the considerable expense associated with the treatment. This elevated cost of treatment pertains to the substantial financial burden linked to medical care. As illustrated by a 2021 study, the expenditure for kernicterus treatment can vary from $570,496 to prevent one case of kernicterus to a lifetime cost of $900,000 for a child with kernicterus. Consequently, the substantial cost of treatment acts as a hindrance to the expansion of the kernicterus treatment market.

Key players in the kernicterus treatment market are actively developing innovative technological products to gain a competitive edge. One such advancement is the creation of wearable devices designed to accurately monitor jaundice. These devices, often small and flexible patches applied to the body based on treatment requirements, contribute to the precision of monitoring. For example, in March 2021, Yokohama National University in Japan introduced the first-ever wearable device for accurate jaundice monitoring. This wearable sensor for infants continuously measures bilirubin levels, facilitating the precise administration of the required amount of blue light to neutralize bilirubin. The device, a small and flexible patch placed on an infant's chest, transmits data to a smartphone or computer, enabling doctors or parents to monitor the condition. It offers enhanced accuracy and convenience compared to traditional jaundice monitoring methods such as blood tests.

In September 2021, Moderna, Inc., a Massachusetts-based pharmaceutical and biotechnology company, collaborated with the Institute for Life Changing Medicines. The partnership's objective is to develop a new mRNA therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease leading to high bilirubin levels and potentially causing kernicterus. This collaboration seeks to provide the mRNA therapy for CN-1 to patients at no cost. The Institute for Life Changing Medicines, a US-based nonprofit organization, focuses on identifying, developing, and promoting access to life-changing medicines for uncommon diseases.

Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc..

North America was the largest region in the kernicterus treatment market in 2023. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kernicterus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kernicterus is an infrequent neurological condition that may manifest in newborns experiencing severe jaundice, marked by elevated levels of bilirubin in the bloodstream. Treatment for kernicterus encompasses medical interventions, therapies, and supportive care, primarily administered to infants and children, with the goal of addressing symptoms, complications, and long-term effects, ultimately enhancing the affected individuals' quality of life.

The primary modalities for treating kernicterus include phototherapy, intravenous immunoglobulins (IVIG), blood transfusion, medication, and other supportive measures. Phototherapy involves the application of light, typically specialized lights or lamps, as a medical intervention. This method is employed to address a range of symptoms associated with kernicterus, such as jaundice, unusual eye movements, vomiting, fever, poor feeding, apnea, irritability, seizures, sleepiness, and others. Dosage administration may take various forms, including injections, solutions, and other delivery methods. The end users of these treatments include clinics, hospitals, and other healthcare facilities.

The kernicterus treatment market research report is one of a series of new reports that provides kernicterus treatment market statistics, including kernicterus treatment industry global market size, regional shares, competitors with a kernicterus treatment market share, detailed kernicterus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. This kernicterus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kernicterus treatment market consists of revenues earned by entities by provide kernicterus treatment services such as diagnostic tests, neurological management, medical evaluation and monitoring and exchange transfusion services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.